July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Compound comparison
BPC-157 vs TB-500
BPC-157 and TB-500 are two of the most discussed peptides in online injury-recovery and performance communities, but they originate from fundamentally different biological sources and act through distinct mechanisms. BPC-157 is a pentadecapeptide derived from human gastric juice with reported angiogenic and anti-inflammatory properties. TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide involved in wound healing and cell migration. Both compounds have been studied primarily in animal models and in vitro systems; published human clinical trial data is scarce for both. Neither BPC-157 nor TB-500 is FDA-approved for any indication, and both are sold as research-use-only compounds subject to FDA enforcement. This comparison documents mechanistic and evidence-level differences; it does not recommend either compound or provide treatment guidance.
Last reviewed 2026-07-08
Next review 2026-08-07
At a glance
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Pentadecapeptide derived from a sequence in human gastric juice protein; first described by Sikiric et al. in the 1990s | Synthetic fragment of Thymosin Beta-4, a naturally occurring peptide expressed in mammalian tissues and involved in wound healing |
| Mechanism | Reported angiogenic and anti-inflammatory effects; promotes new blood vessel formation and modulates inflammatory pathways in animal models | Promotes cell migration and tissue repair via actin sequestration and related pathways; reported angiogenic effects attributed to Thymosin Beta-4 activity |
| Evidence level | Primarily animal studies (rat, mouse) and in vitro data; no published randomized controlled human trials | Primarily animal studies and in vitro data on Thymosin Beta-4; limited evidence specific to the TB-500 synthetic fragment; no published randomized controlled human trials |
| Regulatory status | Not FDA-approved; scheduled for July 2026 PCAC discussion; listed on FDA bulk drug substances risk list | Not FDA-approved; scheduled for July 2026 PCAC discussion; listed on FDA bulk drug substances risk list |
| Supplier availability | Sold by research-use-only vendors; subject to FDA warning letters and enforcement actions | Sold by research-use-only vendors; frequently marketed alongside BPC-157 in recovery-focused peptide discussions |
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, originally identified as a sequence within human gastric juice protein. It was first described in the scientific literature in the 1990s by a Croatian research group (Sikiric et al.) studying gastroprotective agents.
Published preclinical research reports that BPC-157 promotes angiogenesis (new blood vessel formation), exhibits anti-inflammatory effects, and may accelerate healing of tendons, ligaments, muscles, and the gastrointestinal tract in animal models. These effects are documented primarily in rat and mouse studies, including models of gastric ulcer, muscle crush injury, and tendon-to-bone healing.
No published randomized controlled human clinical trials establish efficacy or safety of BPC-157 for any indication. BPC-157 is not FDA-approved. It is scheduled for discussion at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting and appears on the FDA's bulk drug substances risk list. It is sold by research-use-only vendors and is subject to FDA enforcement actions including warning letters.
TB-500 is a synthetic peptide that represents a fragment of Thymosin Beta-4 (TB4), a naturally occurring 43-amino-acid peptide widely expressed in mammalian tissues. Thymosin Beta-4 plays a role in actin sequestration, cell migration, and wound healing. TB-500 is typically marketed as a shorter synthetic fragment intended to capture the biological activity of the parent molecule.
Preclinical and in vitro studies of Thymosin Beta-4 and its fragments report effects on cell migration, angiogenesis, and tissue repair. Some animal studies suggest potential benefit in cardiac, dermal, and corneal injury models. However, the published literature does not clearly distinguish the evidence base for full-length Thymosin Beta-4 from that of TB-500 as a specific synthetic fragment, and the translation of these findings to human therapeutic use is unestablished.
No published randomized controlled human clinical trials establish efficacy or safety of TB-500 as a distinct compound for any indication. TB-500 is not FDA-approved. It is scheduled for discussion at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting and appears on the FDA's bulk drug substances risk list. Like BPC-157, it is sold by research-use-only vendors and is subject to FDA enforcement.
Summary verdict
BPC-157 and TB-500 are both discussed as recovery and healing peptides, but they differ in biological origin and reported mechanism. BPC-157 derives from gastric juice protein and is associated with angiogenic and anti-inflammatory effects. TB-500 is a synthetic fragment of Thymosin Beta-4 and is associated with cell migration and wound healing. Both compounds are supported primarily by animal and in vitro evidence; neither has published human clinical trial data establishing efficacy or safety. Both are unapproved by the FDA, listed on the bulk drug substances risk list, and sold as research-use-only products subject to enforcement. This comparison documents mechanistic and evidence-level differences; it does not recommend either compound or provide treatment guidance.
Sources on this page
Source records are stored in the repo and linked from this comparison.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
Warning Letter: Gram Peptides
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.